Prolonged treatment with boosted protease inhibitor monotherapy is not associated with a higher rate of neurocognitive impairment than triple drug ART

Pérez-Valero, IGonzález-Baeza, AEstébanez, MMontes, MBayon, CPulido, FCambrón, IBernardino, JZamora, FMonge Corella, SusanaGaya, FLagarde, MRubio, RHernando, AGonzález-García, JuanArnalich, FArribas, José R2021-04-292021-04-292012-11J Int AIDS Soc. 2012 Nov 11;15 Suppl 4(Suppl 4):18179.http://hdl.handle.net/20.500.12105/12821Eleventh International Congress on Drug Therapy in HIV Infection, 11-15 November 2012, Glasgow, UK.engVoRhttp://creativecommons.org/licenses/by/4.0/Prolonged treatment with boosted protease inhibitor monotherapy is not associated with a higher rate of neurocognitive impairment than triple drug ARTAtribución 4.0 Internacional156 (Suppl 4)10.7448/IAS.15.6.181791758-2652Journal of the International AIDS Societyopen access